These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
196 related articles for article (PubMed ID: 18787722)
1. Absence of protective effect of renin-angiotensin system inhibitors on atrial fibrillation development: insights from the Canadian Trial of Atrial Fibrillation (CTAF). Palardy M; Ducharme A; Nattel S; Tardif JC; White M; Racine N; Tétreault K; Dabouz F; Talajic M; Roy D; Can J Cardiol; 2008 Sep; 24(9):709-13. PubMed ID: 18787722 [TBL] [Abstract][Full Text] [Related]
2. Old and new antiarrhythmic drugs for converting and maintaining sinus rhythm in atrial fibrillation: comparative efficacy and results of trials. Naccarelli GV; Wolbrette DL; Khan M; Bhatta L; Hynes J; Samii S; Luck J Am J Cardiol; 2003 Mar; 91(6A):15D-26D. PubMed ID: 12670638 [TBL] [Abstract][Full Text] [Related]
3. Cost evaluation of rhythm control methods for atrial fibrillation: evidence from CTAF. Nattel S; Lumer G; Talajic M; Roy D Card Electrophysiol Rev; 2003 Sep; 7(3):211-4. PubMed ID: 14739715 [TBL] [Abstract][Full Text] [Related]
4. Amiodarone to prevent recurrence of atrial fibrillation. Canadian Trial of Atrial Fibrillation Investigators. Roy D; Talajic M; Dorian P; Connolly S; Eisenberg MJ; Green M; Kus T; Lambert J; Dubuc M; Gagné P; Nattel S; Thibault B N Engl J Med; 2000 Mar; 342(13):913-20. PubMed ID: 10738049 [TBL] [Abstract][Full Text] [Related]
5. Quality of life variables in the selection of rate versus rhythm control in patients with atrial fibrillation: observations from the Canadian Trial of Atrial Fibrillation. Dorian P; Mangat I Card Electrophysiol Rev; 2003 Sep; 7(3):276-9. PubMed ID: 14739727 [TBL] [Abstract][Full Text] [Related]
6. Pilot study and protocol of the Canadian Trial of Atrial Fibrillation (CTAF). Roy D; Talajic M; Thibault B; Dubuc M; Nattel S; Eisenberg MJ; Ciampi A Am J Cardiol; 1997 Aug; 80(4):464-8. PubMed ID: 9285659 [TBL] [Abstract][Full Text] [Related]
7. The effect of pretreatment with renin-angiotensin-aldosterone system blockers on cardioversion success and acute recurrence of atrial fibrillation. Dogan A; Akcay S; Karabacak M; Turker Y; Ozaydin M; Erdogan D Int J Clin Pract; 2009 Jul; 63(7):1017-23. PubMed ID: 19570119 [TBL] [Abstract][Full Text] [Related]
8. Prevention of atrial fibrillation by Renin-Angiotensin system inhibition a meta-analysis. Schneider MP; Hua TA; Böhm M; Wachtell K; Kjeldsen SE; Schmieder RE J Am Coll Cardiol; 2010 May; 55(21):2299-307. PubMed ID: 20488299 [TBL] [Abstract][Full Text] [Related]
9. Limitations to antiarrhythmic drug use in patients with atrial fibrillation. Humphries KH; Kerr CR; Steinbuch M; Dorian P; CMAJ; 2004 Sep; 171(7):741-5. PubMed ID: 15451836 [TBL] [Abstract][Full Text] [Related]
10. Efficacy of sequential antiarrhythmic treatment in sinus rhythm maintenance after successful electrocardioversion in patients with chronic non-valvular atrial fibrillation. Kosior D; Opolski G; Torbicki A Med Sci Monit; 2001; 7(1):68-73. PubMed ID: 11208496 [TBL] [Abstract][Full Text] [Related]
11. Amiodarone reduces procedures and costs related to atrial fibrillation in a controlled clinical trial. Lumer GB; Roy D; Talajic M; Couturier A; Lambert J; Frasure-Smith N; Thibault B; Dubuc M; Gagné P; Nattel S Eur Heart J; 2002 Jul; 23(13):1050-6. PubMed ID: 12093058 [TBL] [Abstract][Full Text] [Related]
12. Canadian Cardiovascular Society atrial fibrillation guidelines 2010: rate and rhythm management. Gillis AM; Verma A; Talajic M; Nattel S; Dorian P; Can J Cardiol; 2011; 27(1):47-59. PubMed ID: 21329862 [TBL] [Abstract][Full Text] [Related]
13. Systematic electrocardioversion for atrial fibrillation and role of antiarrhythmic drugs: a substudy of the SAFE-T trial. Singh SN; Tang XC; Reda D; Singh BN Heart Rhythm; 2009 Feb; 6(2):152-5. PubMed ID: 19187902 [TBL] [Abstract][Full Text] [Related]
14. Long-term efficacy and safety of propafenone and sotalol for the maintenance of sinus rhythm after conversion of recurrent symptomatic atrial fibrillation. Bellandi F; Simonetti I; Leoncini M; Frascarelli F; Giovannini T; Maioli M; Dabizzi RP Am J Cardiol; 2001 Sep; 88(6):640-5. PubMed ID: 11564387 [TBL] [Abstract][Full Text] [Related]
16. A comparison between oral antiarrhythmic drugs in the prevention of atrial fibrillation after cardiac surgery: the pilot study of prevention of postoperative atrial fibrillation (SPPAF), a randomized, placebo-controlled trial. Auer J; Weber T; Berent R; Puschmann R; Hartl P; Ng CK; Schwarz C; Lehner E; Strasser U; Lassnig E; Lamm G; Eber B; Am Heart J; 2004 Apr; 147(4):636-43. PubMed ID: 15077078 [TBL] [Abstract][Full Text] [Related]
17. Propafenone versus sotalol for suppression of recurrent symptomatic atrial fibrillation. Reimold SC; Cantillon CO; Friedman PL; Antman EM Am J Cardiol; 1993 Mar; 71(7):558-63. PubMed ID: 8438741 [TBL] [Abstract][Full Text] [Related]
18. Quality of life improves with treatment in the Canadian Trial of Atrial Fibrillation. Dorian P; Paquette M; Newman D; Green M; Connolly SJ; Talajic M; Roy D Am Heart J; 2002 Jun; 143(6):984-90. PubMed ID: 12075253 [TBL] [Abstract][Full Text] [Related]
19. Atrial fibrillation: rate control often better than rhythm control. Prescrire Int; 2004 Apr; 13(70):64-9. PubMed ID: 15148984 [TBL] [Abstract][Full Text] [Related]
20. Maintenance of sinus rhythm in patients with atrial fibrillation: an AFFIRM substudy of the first antiarrhythmic drug. AFFIRM First Antiarrhythmic Drug Substudy Investigators J Am Coll Cardiol; 2003 Jul; 42(1):20-9. PubMed ID: 12849654 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]